Navigation Links
Fewer adverse cardiac events at one year
Date:10/23/2007

WASHINGTON, DC OCTOBER 22, 2007 Late breaking results from the SPIRIT III trial, presented at TCT 2007, the annual scientific symposium of the Cardiovascular Research Foundation, show that after 12 months, there were significantly fewer major adverse cardiac events (MACE) such as heart attacks, deaths from cardiac causes or repeat procedures (angioplasty or surgery) to clear the original vessel blockage after using a Xience V everolimus-eluting coronary stent than a Taxus paclitaxel-eluting stent.

The rate of the primary endpoint, in-segment late loss (a measure of how much the artery re-narrows following stenting) was also reduced by 50% with the Xience V stent compared to Taxus. There were no significant differences in other secondary endpoints between the two stent types, including target vessel failure (a combination of repeat procedures anywhere in the involved blood vessel and adverse cardiac events), as well as stent thrombosis (dangerous blood clots that can form within the stent).

Both the primary endpoint of the trial and the major secondary endpoint were met, said Gregg W. Stone, MD, Chairman, Cardiovascular Research Foundation and Professor of Medicine, Columbia University Medical Center. Moreover, the reduction in major adverse cardiac events with the Xience V stent compared to the Taxus stent is an important finding that signifies improved long-term outcomes for patients with heart disease. Given this positive finding, which has never before been seen in a pivotal drug-eluting stent vs. stent trial, coupled with the ease of use of Xience, will result in this device becoming a favored drug-eluting stent for clinicians treating coronary disease.

Further studies are required to determine whether there are meaningful differences between the two stent types in low frequency safety events, and in important subgroups, Stone added.

SPIRIT III 12-Month Results

Everolimus-Eluting Stent Paclitaxel-Eluting Stent
Target Vessel Failure 8.3 percent 10.8 percent
MACE 5.8 percent 9.9 percent
Cardiac Death .8 percent .9 percent
MI 2.6 percent 3.7 percent
Ischemia-Driven TLR 3.3 percent 5.6 percent

The SPIRIT III trial was designed as a prospective, randomized, active-controlled, single blind, multi-center clinical trial, which enrolled 1,002 patients (65 different U.S. sites) with coronary artery disease.


'/>"/>

Contact: Irma Damhuis
idamhuis@crf.org
917-558-5180
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Chemotherapy Pill Has Fewer Side Effects Than IV
2. Fewer teeth & Increased Ischemic Stroke risk
3. Heart Patients More At Risk Get Fewer Medicines
4. Fewer People Die Due To Cancer
5. Fewer Breast Cancer Patients to Get Chemo
6. Fewer Blacks Undergo Lung Cancer Surgery
7. Thailand had Fewer AIDS-Related Deaths, New HIV Cases In 2005
8. Fewer Neurons in Amygdala of Autistic Males
9. Women With Fewer Periods Have Low Risk Of Gynecological Cancer
10. Fewer Doctors Treating For Free
11. Fruits & Vegetables Makes You Look Younger With Fewer Wrinkles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... for human induced pluripotent stem (iPS) cells and other difficult to transfect cells, ... Cloning Medium. The PluriQ™ G9™ Gene Editing System is a complete ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 Research ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural Health ... Structural electronics involves electronic and/or electrical ... structures, replacing dumb structures such as vehicle bodies ...
(Date:6/24/2016)... CLEMENTE, Calif. , June 24, 2016  American Respiratory Labs ... company, is now able to perform sophisticated lung assessments in patients, ... Technologies , Inc. Patients are no longer limited ... ndd,s EasyOne PRO ® , ARL patients like Jeanne R. of ... done in the comfort of her own home. ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology: